Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

Y0001460

Acetylsalicylic acid for peak identification

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Acetylsalicylic acid, 2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula condensata:
2-(CH3CO2)C6H4CO2H
Numero CAS:
50-78-2
Peso molecolare:
180.16
Beilstein:
779271
Numero MDL:
MFCD00002430
Codice UNSPSC:
41116107
ID PubChem:
329831434
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

aspirin

Produttore/marchio commerciale

EDQM

Punto di fusione

134-136 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Informazioni sul gene

human ... PTGS1(5742) , PTGS2(5743)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Acetylsalicylic acid for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

PHR1003

Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material

1044006

Aspirin, United States Pharmacopeia (USP) Reference Standard

A0200000

Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard

1609807

Salsalate, United States Pharmacopeia (USP) Reference Standard

1696200

Trisalicylic acid, United States Pharmacopeia (USP) Reference Standard

BP617

Aspirin, British Pharmacopoeia (BP) Reference Standard

PHR1940

Aspirin Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1941

Aspirin Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1942

Aspirin Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

482.0 °F

Punto d’infiammabilità (°C)

250 °C

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Clotrimazole for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000849

Clotrimazole for peak identification

Aspirin Impurity E Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1941

Aspirin Impurity E

Salicylic acid United States Pharmacopeia (USP) Reference Standard

USP

1609002

Salicylic acid

Aspirin meets USP testing specifications

Sigma-Aldrich

A2093

Aspirin

Salicylic acid for synthesis

Sigma-Aldrich

8.18731

Salicylic acid

Salicylic acid Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1013

Salicylic acid

Salicylic acid BioXtra, ≥99.0%

Sigma-Aldrich

S5922

Salicylic acid

Acido fosforico 85 wt. % in H2O, FCC, FG

Sigma-Aldrich

W290017

Acido fosforico

Yu-Chi Tung et al.
Medical care, 52(6), 519-527 (2014-05-03)
A volume-outcome relationship has been found for acute myocardial infarction (AMI); however, the mechanisms underlying the relationship remain unclear. In particular, it is not known whether processes of care are mediators of the volume-outcome relationship, that is, whether the mechanisms
Gideon Sahar et al.
The Journal of thoracic and cardiovascular surgery, 149(4), 1042-1050 (2015-04-25)
We compared the flow rates, reactivity, and morphology of the distal internal thoracic artery and its branches, the superior epigastric and musculophrenic arteries, to test their applicability as possible conduits in coronary artery bypass grafting surgeries. Skeletonized internal thoracic artery
Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Yasuo Ikeda et al.
JAMA, 312(23), 2510-2520 (2014-11-18)
Prevention of atherosclerotic cardiovascular diseases is an important public health priority in Japan due to an aging population. To determine whether daily, low-dose aspirin reduces the incidence of cardiovascular events in older Japanese patients with multiple atherosclerotic risk factors. The
Sigrun Halvorsen et al.
Journal of the American College of Cardiology, 64(3), 319-327 (2014-07-19)
Although the use of oral anticoagulants (vitamin K antagonists) has been abandoned in primary cardiovascular prevention due to lack of a favorable benefit-to-risk ratio, the indications for aspirin use in this setting continue to be a source of major debate
Visualizza tutti i documenti correlati

Articoli

HPLC Analysis of Pain Relievers on Ascentis® Express C18

Separation of Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder; Caffeine, meets USP testing specifications, anhydrous; Benzoic acid, meets USP testing specifications; Aspirin, meets USP testing specifications

Protocolli

HPLC Analysis of Aspirin and Salicylic Acid on Ascentis® Express RP-Amide

Separation of Acetylsalicylic acid, analytical standard; Salicylic acid, BioXtra, ≥99.0%

HPLC Analysis of Salicylic Acid and Acetylsalicylic Acid (Aspirin) on Ascentis® Express OH5

Separation of Salicylic acid, meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (calc. to the dried substance); Acetylsalicylic acid, purum, ≥99.0% (HPLC)

HPLC Analysis of Benzoic Acid and Related Compounds on Ascentis® RP-Amide

Separation of 4-Hydroxybenzoic acid; Acetylsalicylic acid; Benzoic acid; Salicylic acid; Ethyl 4-hydroxybenzoate

HPLC Analysis of Benzoic Acid Derivatives on Ascentis® C18

HPLC Analysis of Benzoic Acid Derivatives on Ascentis® C18

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.